Cleerly ISCHEMIA vs Tempus ECG-Low EF
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a detailed, non-invasive assessment of coronary artery disease and vessel-level ischemia based on CCTA scans. This tool is ideal for physicians needing comprehensive insights into plaque characteristics, stenosis severity, and fractional flow reserve estimation to guide personalized diagnosis and treatment planning for heart disease.
View Cleerly ISCHEMIA →Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if you need a rapid, AI-powered screening tool to identify patients 40 years or older at risk of heart failure by detecting signs associated with low left ventricular ejection fraction (LVEF ≤40%) from standard 12-lead ECG recordings. This is particularly useful for broad risk stratification and determining which patients may require further, more definitive cardiac evaluation.
View Tempus ECG-Low EF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | Tempus ECG-Low EF |
|---|---|---|
| Deployment | Web-based solution | Integrates with current ECG platforms and electronic health records (EHRs). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIATool A (Cleerly ISCHEMIA) emphasizes a 'Web-based platform' with 'Comprehensive interactive web-based reports' and 'Integration with PowerScribe via API', suggesting a highly interactive and integrated user experience. Tool B (Tempus ECG-Low EF) provides a 'binary output,' which is simple but offers less detailed interaction or reporting capabilities for clinicians.
Clinical Value
Cleerly ISCHEMIATool A (Cleerly ISCHEMIA) offers a more comprehensive and granular analysis, including non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood, coronary plaque characterization, and 3D digital models, aiding in personalized diagnosis and treatment planning. While Tool B (Tempus ECG-Low EF) provides valuable screening for low LVEF, its binary output offers less detailed clinical insight compared to Tool A's multi-faceted assessment.
Pricing & Value
TieBoth tools state 'contact for details' or 'contact vendor' for pricing, making it impossible to compare their cost-effectiveness or overall value. Without transparent pricing models or publicly available cost-benefit analyses, a definitive winner cannot be determined in this dimension.
Enterprise Readiness
Cleerly ISCHEMIABoth tools are FDA-cleared, HIPAA compliant, and have BAAs, indicating foundational enterprise readiness. However, Tool A (Cleerly ISCHEMIA) explicitly mentions robust deployment options like 'Cleerly Proxy (VPN or virtual appliance)' for data transfer and 'Integration with PowerScribe via API,' suggesting more detailed and flexible integration capabilities for healthcare facilities.
Innovation
Cleerly ISCHEMIATool A (Cleerly ISCHEMIA)'s ability to non-invasively estimate fractional flow reserve (FFR) and provide detailed coronary plaque characterization from CCTA scans represents a significant advancement in non-invasive cardiac diagnostics. While Tool B (Tempus ECG-Low EF) applies AI to ECGs for LVEF detection, the depth and breadth of insights provided by Tool A appear to push the boundaries of current diagnostic capabilities further.
Support & Docs
Cleerly ISCHEMIAWhile both companies likely offer standard customer support, Cleerly (Tool A) explicitly mentions 'Cleerly Academy' for education and training and 'Cleerly Connect' for customer support on its website, suggesting a more structured and formalized approach to user enablement and assistance. Tempus (Tool B) provides general contact information for support inquiries but less specific details about dedicated programs for documentation and user support.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | Tempus ECG-Low EF |
|---|---|---|
| Tool Name | Cleerly ISCHEMIA | Tempus ECG-Low EF |
| Primary Function | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. |
| Input Data Type | CCTA scans | 12-lead ECG recordings |
| Key Output | Vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), stenosis severity assessment, non-invasive fractional flow reserve (FFR) estimation. | Binary output (Low LVEF Detected / Not Detected) |
| Target Condition/Population | Coronary artery ischemia, heart disease. | Low left ventricular ejection fraction (LVEF u226440%), patients 40+ years at risk of heart failure. |
| Supported Specialties | Cardiology, Radiology | Cardiology, Emergency Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and Tempus ECG-Low EF.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or Tempus ECG-Low EF
Backers
Who funded each tool's parent company.